What we are studying
The objectives of this study are to evaluate the safety and efficacy of a new drug when administered in combination with Lucentis® compared to Lucentis® alone in people with wet age-related macular degeneration (AMD). In the "wet" form of AMD, abnormal blood vessels grow in the back of the eye. Sometimes these vessels leak blood or fluid that causes blurred or distorted vision. This process is also known as choroidal neovascularization (CNV).